H-0603.3

## HOUSE BILL 1520

State of Washington 69th Legislature 2025 Regular Session

By Representatives Thai, Reed, Simmons, and Macri

Read first time 01/22/25. Referred to Committee on Health Care & Wellness.

- AN ACT Relating to expanding pharmacists' scope of practice to improve access to health care and the management of chronic diseases; amending RCW 69.41.030; reenacting and amending RCW 18.64.011; adding a new section to chapter 18.64 RCW; creating new sections; and providing an expiration date.
- 6 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
- 7 NEW SECTION. Sec. 1. The legislature recognizes pharmacists as highly educated health care professionals uniquely qualified to 8 prescribe medications and devices to improve patient outcomes. Being 9 10 deeply concerned about provider shortages in Washington, particularly in rural and underserved communities, the legislature seeks to expand 11 12 access to care by leveraging pharmacists' expertise. It is the intent 13 of the legislature to improve patient outcomes for behavioral and 14 physical health by permitting pharmacists to practice at the top of 15 their education, training, and experience.
- Sec. 2. RCW 18.64.011 and 2024 c 121 s 30 are each reenacted and amended to read as follows:
- The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.

p. 1 HB 1520

(1) "Administer" means the direct application of a drug or device, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject.

- (2) "Business licensing system" means the mechanism established by chapter 19.02 RCW by which business licenses, endorsed for individual state-issued licenses, are issued and renewed utilizing a business license application and a business license expiration date common to each renewable license endorsement.
- (3) "Chart order" means a lawful order for a drug or device entered on the chart or medical record of an inpatient or resident of an institutional facility by a practitioner or his or her designated agent.
  - (4) "Closed door long-term care pharmacy" means a pharmacy that provides pharmaceutical care to a defined and exclusive group of patients who have access to the services of the pharmacy because they are treated by or have an affiliation with a long-term care facility or hospice program, and that is not a retailer of goods to the general public.
    - (5) "Commission" means the pharmacy quality assurance commission.
  - (6) "Compounding" means the act of combining two or more ingredients in the preparation of a prescription. Reconstitution and mixing of (a) sterile products according to federal food and drug administration-approved labeling does not constitute compounding if prepared pursuant to a prescription and administered immediately or in accordance with package labeling, and (b) nonsterile products according to federal food and drug administration-approved labeling does not constitute compounding if prepared pursuant to a prescription.
  - (7) "Controlled substance" means a drug or substance, or an immediate precursor of such drug or substance, so designated under or pursuant to the provisions of chapter 69.50 RCW.
  - (8) "Deliver" or "delivery" means the actual, constructive, or attempted transfer from one person to another of a drug or device, whether or not there is an agency relationship.
    - (9) "Department" means the department of health.
  - (10) "Device" means instruments, apparatus, and contrivances, including their components, parts, and accessories, intended (a) for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in human beings or other animals, or (b) to affect the

p. 2 HB 1520

1 structure or any function of the body of human beings or other 2 animals.

- (11) "Directed plan of correction" means a plan devised by the commission that includes specific actions that must be taken to correct identified unresolved deficiencies with time frames to complete them.
- (12) "Dispense" means the interpretation of a prescription or order for a drug, biological, or device and, pursuant to that prescription or order, the proper selection, measuring, compounding, labeling, or packaging necessary to prepare that prescription or order for delivery.
- 12 (13) "Distribute" means the delivery of a drug or device other 13 than by administering or dispensing.
  - (14) "Drug" and "devices" do not include surgical or dental instruments or laboratory materials, gas and oxygen, therapy equipment, X-ray apparatus or therapeutic equipment, their component parts or accessories, or equipment, instruments, apparatus, or contrivances used to render such articles effective in medical, surgical, or dental treatment, or for use or consumption in or for mechanical, industrial, manufacturing, or scientific applications or purposes. "Drug" also does not include any article or mixture covered by the Washington pesticide control act (chapter 15.58 RCW), as enacted or hereafter amended, nor medicated feed intended for and used exclusively as a feed for animals other than human beings.
    - (15) "Drugs" means:

- (a) Articles recognized in the official United States pharmacopoeia or the official homeopathic pharmacopoeia of the United States;
- (b) Substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in human beings or other animals;
- (c) Substances (other than food) intended to affect the structure or any function of the body of human beings or other animals; or
- (d) Substances intended for use as a component of any substances specified in (a), (b), or (c) of this subsection, but not including devices or their component parts or accessories.
- (16) "Health care entity" means an organization that provides health care services in a setting that is not otherwise licensed by the state to acquire or possess legend drugs. Health care entity includes a freestanding outpatient surgery center, a residential

p. 3 HB 1520

- treatment facility, and a freestanding cardiac care center. "Health care entity" does not include an individual practitioner's office or a multipractitioner clinic, regardless of ownership, unless the owner elects licensure as a health care entity. "Health care entity" also does not include an individual practitioner's office or multipractitioner clinic identified by a hospital on a pharmacy application or renewal pursuant to RCW 18.64.043.
  - (17) "Hospice program" means a hospice program certified or paid by medicare under Title XVIII of the federal social security act, or a hospice program licensed under chapter 70.127 RCW.

8

9

10 11

12

13

14

1516

17

18

1920

21

26

27

28

29

30 31

32

33

34

3536

- (18) "Immediate jeopardy" means a situation in which a licensee's noncompliance with one or more statutory or regulatory requirements has placed the health and safety of individuals or animals at risk for serious injury, serious harm, serious impairment, or death.
- (19) "Institutional facility" means any organization whose primary purpose is to provide a physical environment for patients to obtain health care services including, but not limited to, services in a hospital, long-term care facility, hospice program, mental health facility, drug abuse treatment center, residential habilitation center, or a local, state, or federal correction facility.
- (20) "Labeling" means the process of preparing and affixing a label to any drug or device container. The label must include all information required by current federal and state law and pharmacy rules.
  - (21) "Legend drugs" means any drugs which are required by any applicable federal or state law or regulation to be dispensed on prescription only or are restricted to use by practitioners only.
  - (22) "License," "licensing," and "licensure" shall be deemed equivalent to the terms "approval," "credential," "certificate," "certification," "permit," and "registration" and an "exemption" issued under chapter 69.50 RCW.
  - (23) "Long-term care facility" means a nursing home licensed under chapter 18.51 RCW, an assisted living facility licensed under chapter 18.20 RCW, or an adult family home licensed under chapter 70.128 RCW.
- 37 (24) "Manufacture" means the production, preparation, 38 propagation, compounding, or processing of a drug or other substance 39 or device or the packaging or repackaging of such substance or 40 device, or the labeling or relabeling of the commercial container of

p. 4 HB 1520

such substance or device, but does not include the activities of a practitioner who, as an incident to his or her administration or dispensing such substance or device in the course of his or her professional practice, personally prepares, compounds, packages, or labels such substance or device. "Manufacture" includes the distribution of a licensed pharmacy compounded drug product to other state licensed persons or commercial entities for subsequent resale or distribution, unless a specific product item has approval of the commission. The term does not include:

- (a) The activities of a licensed pharmacy that compounds a product on or in anticipation of an order of a licensed practitioner for use in the course of their professional practice to administer to patients, either personally or under their direct supervision;
- (b) The practice of a licensed pharmacy when repackaging commercially available medication in small, reasonable quantities for a practitioner legally authorized to prescribe the medication for office use only;
- (c) The distribution of a drug product that has been compounded by a licensed pharmacy to other appropriately licensed entities under common ownership or control of the facility in which the compounding takes place; or
- (d) The delivery of finished and appropriately labeled compounded products dispensed pursuant to a valid prescription to alternate delivery locations, other than the patient's residence, when requested by the patient, or the prescriber to administer to the patient, or to another licensed pharmacy to dispense to the patient.
- (25) "Manufacturer" means a person, corporation, or other entity engaged in the manufacture of drugs or devices.
- (26) "Nonlegend" or "nonprescription" drugs means any drugs which may be lawfully sold without a prescription.
- 31 (27) "Person" means an individual, corporation, government, 32 governmental subdivision or agency, business trust, estate, trust, 33 partnership or association, or any other legal entity.
  - (28) "Pharmacist" means a person duly licensed by the commission to engage in the practice of pharmacy.
- 36 (29) "Pharmacy" means every place properly licensed by the 37 commission where the practice of pharmacy is conducted.
- 38 (30) "Plan of correction" means a proposal devised by the 39 applicant or licensee that includes specific actions that must be

p. 5 HB 1520

taken to correct identified unresolved deficiencies with the time
frames to complete them.

3

4

5

22

2324

25

26

2728

31

32

33

3435

36

37

38

39

- (31) "Poison" does not include any article or mixture covered by the Washington pesticide control act (chapter 15.58 RCW), as enacted or hereafter amended.
- 6 (32)"Practice of pharmacy" includes the practice of and 7 responsibility for: Interpreting prescription orders; the compounding, dispensing, labeling, administering, and distributing of 8 drugs and devices; the monitoring of drug therapy and use; the 9 initiating or modifying of drug therapy in accordance with written 10 11 guidelines or protocols previously established and approved for his 12 or her practice by a practitioner authorized to prescribe drugs; the diagnosing of conditions and diseases as authorized by this chapter 13 and commission rules; the prescribing or ordering of drugs and 14 devices as authorized by this chapter and commission rules; the 15 16 participating in drug utilization reviews and drug product selection; 17 the proper and safe storing and distributing of drugs and devices and maintenance of proper records thereof; the providing of information 18 19 on legend drugs which may include, but is not limited to, the advising of therapeutic values, hazards, and the uses of drugs and 20 21 devices.
  - (33) "Practitioner" means a physician, dentist, veterinarian, nurse, or other person duly authorized by law or rule in the state of Washington to prescribe drugs.
  - (34) "Prescription" means an order for drugs or devices issued by a practitioner duly authorized by law or rule in the state of Washington to prescribe drugs or devices in the course of his or her professional practice for a legitimate medical purpose.
- 29 (35) "Secretary" means the secretary of health or the secretary's designee.
  - (36) "Shared pharmacy services" means a system that allows a participating pharmacist or pharmacy pursuant to a request from another participating pharmacist or pharmacy to process or fill a prescription or drug order, which may include but is not necessarily limited to preparing, packaging, labeling, data entry, compounding for specific patients, dispensing, performing drug utilization reviews, conducting claims adjudication, obtaining refill authorizations, reviewing therapeutic interventions, or reviewing chart orders.

p. 6 HB 1520

- 1 (37) "Statement of deficiency" means a written statement of the 2 deficiencies prepared by the commission, or its designee, identifying 3 one or more violations of law. The report clearly identifies the 4 specific law or rule that has been violated along with a description 5 of the reasons for noncompliance.
- 6 (38) "Wholesaler" means a corporation, individual, or other 7 entity which buys drugs or devices for resale and distribution to 8 corporations, individuals, or entities other than consumers.
- 9 <u>NEW SECTION.</u> **Sec. 3.** A new section is added to chapter 18.64 10 RCW to read as follows:
- 11 (1) Beginning December 1, 2026, a pharmacist may prescribe the 12 following:
- 13 (a) Immunizations;
- 14 (b) Opioid antagonists and treatments for addiction;
- 15 (c) Epinephrine autoinjectors;
- (d) Antihistamine agents;
- 17 (e) Tobacco cessation products;
- 18 (f) Medications to prevent human immunodeficiency virus;
- 19 (g) Tuberculin purified protein derivative products;
- 20 (h) Hormonal contraception;
- 21 (i) Medications to treat or prevent diseases related to travel; 22 and
- 23 (j) Drugs, drug categories, or devices that are limited to 24 conditions that:
- 25 (i) Do not require a new diagnosis;
- 26 (ii) Are minor and generally self-limiting;
- (iii) Have a test that is used to guide diagnosis or clinical decision making and are waived under the federal clinical laboratory improvement amendments of 1988;
- 30 (iv) Are devices waived under the federal clinical laboratory 31 improvement amendments of 1988; or
- 32 (v) Are prescribed in team-based practices with a shared medical record.
- 34 (2) This section expires January 1, 2030.
- 35 **Sec. 4.** RCW 69.41.030 and 2024 c 102 s 2 are each amended to 36 read as follows:
- 37 (1) It shall be unlawful for any person to sell or deliver any 38 legend drug, or knowingly possess any legend drug, or knowingly use

p. 7 HB 1520

any legend drug in a public place, except upon the order or 1 prescription of a physician under chapter 18.71 RCW, an osteopathic 2 physician and surgeon under chapter 18.57 RCW, an optometrist 3 licensed under chapter 18.53 RCW who is certified by the optometry 4 board under RCW 18.53.010, a dentist under chapter 18.32 RCW, a 5 6 podiatric physician and surgeon under chapter 18.22 RCW, a licensed midwife to the extent authorized under chapter 18.50 RCW, 7 veterinarian under chapter 18.92 RCW, a commissioned medical or 8 dental officer in the United States armed forces or public health 9 10 service in the discharge of his or her official duties, a duly licensed physician or dentist employed by the veterans administration 11 12 in the discharge of his or her official duties, a registered nurse or advanced registered nurse practitioner under chapter 18.79 RCW when 13 authorized by the board of nursing, a pharmacist licensed under 14 15 chapter 18.64 RCW to the extent permitted ((by drug therapy 16 guidelines or protocols established under RCW 18.64.011 and 17 authorized by the commission and approved by a practitioner authorized to prescribe drugs)) under chapter 18.64 RCW, a physician 18 19 assistant under chapter 18.71A RCW when authorized by the Washington medical commission, or any of the following professionals in any 20 21 province of Canada that shares a common border with the state of Washington or in any state of the United States: A physician licensed 22 23 to practice medicine and surgery or a physician licensed to practice osteopathic medicine and surgery, a dentist licensed to practice 24 25 dentistry, a podiatric physician and surgeon licensed to practice podiatric medicine and surgery, a licensed advanced registered nurse 26 27 practitioner, a licensed physician assistant, or a veterinarian 28 licensed to practice veterinary medicine: PROVIDED, HOWEVER, That the 29 above provisions shall not apply to sale, delivery, or possession by drug wholesalers or drug manufacturers, or their agents or employees, 30 31 or to any practitioner acting within the scope of his or her license, 32 or to a common or contract carrier or warehouse operator, or any employee thereof, whose possession of any legend drug is in the usual 33 course of business or employment: PROVIDED FURTHER, That nothing in 34 this chapter or chapter 18.64 RCW shall prevent a family planning 35 clinic that is under contract with the health care authority from 36 37 selling, delivering, possessing, and dispensing commercially prepackaged oral contraceptives prescribed by authorized, licensed 38 39 health care practitioners: PROVIDED FURTHER, That nothing in this 40 chapter prohibits possession or delivery of legend drugs by an

p. 8 HB 1520

authorized collector or other person participating in the operation of a drug take-back program authorized in chapter 69.48 RCW.

1

2

3

4

5

7

8

12

13

14

1516

17

18

19

2021

22

2324

- (2) (a) A violation of this section involving the sale, delivery, or possession with intent to sell or deliver is a class B felony punishable according to chapter 9A.20 RCW.
- (b) A violation of this section involving knowing possession is a misdemeanor. The prosecutor is encouraged to divert such cases for assessment, treatment, or other services.
- 9 (c) A violation of this section involving knowing use in a public 10 place is a misdemeanor. The prosecutor is encouraged to divert such 11 cases for assessment, treatment, or other services.
  - (d) No person may be charged with both knowing possession and knowing use in a public place under this section relating to the same course of conduct.
  - (e) In lieu of jail booking and referral to the prosecutor for a violation of this section involving knowing possession, or knowing use in a public place, law enforcement is encouraged to offer a referral to assessment and services available under RCW 10.31.110 or other program or entity responsible for receiving referrals in lieu of legal system involvement, which may include, but are not limited to, arrest and jail alternative programs established under RCW 36.28A.450, law enforcement assisted diversion programs established under RCW 71.24.589, and the recovery navigator program established under RCW 71.24.115.
- 25 (3) For the purposes of this section, "public place" has the same 26 meaning as defined in RCW 66.04.010, but the exclusions in RCW 27 66.04.011 do not apply.
- 28 (4) For the purposes of this section, "use any legend drug" means 29 to introduce the drug into the human body by injection, inhalation, 30 ingestion, or any other means.
- NEW SECTION. Sec. 5. The pharmacy quality assurance commission may adopt rules to administer and implement this act.

--- END ---

p. 9 HB 1520